Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.370
-0.030 (-2.14%)
At close: Apr 28, 2026, 4:00 PM EDT
1.353
-0.017 (-1.21%)
After-hours: Apr 28, 2026, 6:59 PM EDT
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cardiol Therapeutics stock have an average target of 8.50, with a low estimate of 8.00 and a high estimate of 9.00. The average target predicts an increase of 520.44% from the current stock price of 1.37.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cardiol Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +483.94% | Apr 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +556.93% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +556.93% | Dec 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +556.93% | Jun 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +556.93% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
9.74M
EPS This Year
-0.53
from -0.39
EPS Next Year
-0.13
from -0.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 33.9M | ||||||
| Avg | n/a | 9.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.28 | -0.04 | ||||||
| Avg | -0.53 | -0.13 | ||||||
| Low | -0.94 | -0.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.